16 research outputs found
Diagnosis of biliary tract and ampullary carcinomas
Diagnostic methods for biliary tract carcinoma and the efficacy of these methods are discussed. Neither definite methods for early diagnosis nor specific markers are available in this disease. When this disease is suspected on the basis of clinical symptoms and risk factors, hemato-biochemical examination and abdominal ultrasonography are performed and, where appropriate, enhanced computed tomography (CT) and/or magnetic resonance cholangiopancreatography (MRCP) is carried out. Diagnoses of extrahepatic bile duct cancer and ampullary carcinoma are often made based on the presence of obstructive jaundice. Although rare, abdominal pain and pyrexia, as well as abnormal findings of the hepatobiliary system detected by hemato-biochemical examination, serve as a clue to making a diagnosis of these diseases. On the other hand, the early diagnosis of gallbladder cancer is scarcely possible on the basis of clinical symptoms, so when this cancer is found with the onset of abdominal pain and jaundice, it is already advanced at the time of detection, thus making a cure difficult. When gallbladder cancer is suspected, enhanced CT is carried out. Multidetector computed tomography (MDCT), in particular — one of the methods of enhanced CT — is useful for decision of surgical criteria, because MDCT shows findings such as localization and extension of the tumor, and the presence or absence of remote metastasis. Procedures such as magnetic resonance imaging, endoscopic ultrasonography, bile duct biopsy, and cholangioscopy should be carried out taking into account indications for these procedures in individual patients. However, direct biliary tract imaging is necessary for making a precise diagnosis of the horizontal extension of bile duct cancer
Driver Fusions and Their Implications in the Development and Treatment of Human Cancers.
Gene fusions represent an important class of somatic alterations in cancer. We systematically investigated fusions in 9,624 tumors across 33 cancer types using multiple fusion calling tools. We identified a total of 25,664 fusions, with a 63% validation rate. Integration of gene expression, copy number, and fusion annotation data revealed that fusions involving oncogenes tend to exhibit increased expression, whereas fusions involving tumor suppressors have the opposite effect. For fusions involving kinases, we found 1,275 with an intact kinase domain, the proportion of which varied significantly across cancer types. Our study suggests that fusions drive the development of 16.5% of cancer cases and function as the sole driver in more than 1% of them. Finally, we identified druggable fusions involving genes such as TMPRSS2, RET, FGFR3, ALK, and ESR1 in 6.0% of cases, and we predicted immunogenic peptides, suggesting that fusions may provide leads for targeted drug and immune therapy
Evolutionarily Ancient Association of the FoxJ1 Transcription Factor with the Motile Ciliogenic Program
10.1371/journal.pgen.1003019PLoS Genetics811e100301
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study.
Clinical benefits of atezolizumab plus bevacizumab (atezolizumab-bevacizumab) are observed only in a subset of patients with hepatocellular carcinoma and the development of biomarkers is needed to improve therapeutic strategies. The atezolizumab-bevacizumab response signature (ABRS), assessed by molecular biology profiling techniques, has been shown to be associated with progression-free survival after treatment initiation. The primary objective of our study was to develop an artificial intelligence (AI) model able to estimate ABRS expression directly from histological slides, and to evaluate if model predictions were associated with progression-free survival.
In this multicentre retrospective study, we developed a model (ABRS-prediction; ABRS-P), which was derived from the previously published clustering-constrained attention multiple instance learning (or CLAM) pipeline. We trained the model fit for regression analysis using a multicentre dataset from The Cancer Genome Atlas (patients treated by surgical resection, n=336). The ABRS-P model was externally validated on two independent series of samples from patients with hepatocellular carcinoma (a surgical resection series, n=225; and a biopsy series, n=157). The predictive value of the model was further tested in a series of biopsy samples from a multicentre cohort of patients with hepatocellular carcinoma treated with atezolizumab-bevacizumab (n=122). All samples in the study were from adults (aged ≥18 years). The validation sets were sampled between Jan 1, 2008, to Jan 1, 2023. For the multicentre validation set, the primary objective was to assess the association of high versus low ABRS-P values, defined relative to cross-validation median split thresholds in the first biopsy series, with progression-free survival after treatment initiation. Finally, we performed spatial transcriptomics and matched prediction heatmaps with in situ expression profiles.
Of the 840 patients sampled, 641 (76%) were male and 199 (24%) were female. Across the development and validation datasets, hepatocellular carcinoma risk factors included alcohol intake, hepatitis B and C virus infections, and non-alcoholic steatohepatitis. Using cross-validation in the development series, the mean Pearson's correlation between ABRS-P values and ABRS score (mean expression of ABRS genes) was r=0·62 (SD 0·09; mean p<0·0001, SD<0·0001). The ABRS-P generalised well on the external validation series (surgical resection series, r=0·60 [95% CI 0·51-0·68], p<0·0001; biopsy series, r=0·53 [0·40-0·63], p<0·0001). In the 122 patients treated with atezolizumab-bevacizumab, those with ABRS-P-high tumours (n=74) showed significantly longer median progression-free survival than those with ABRS-P-low tumours (n=48) after treatment initiation (12 months [95% CI 7-not reached] vs 7 months [4-9]; p=0·014). Spatial transcriptomics showed significantly higher ABRS score, along with upregulation of various other immune effectors, in tumour areas with high ABRS-P values versus areas with low ABRS-P values.
Our study indicates that AI applied on hepatocellular carcinoma digital slides is able to serve as a biomarker for progression-free survival in patients treated with atezolizumab-bevacizumab. This approach could be used in the development of inexpensive and fast biomarkers for targeted therapies. The combination of AI heatmaps with spatial transcriptomics provides insight on the molecular features associated with predictions. This methodology could be applied to other cancers or diseases and improve understanding of the biological mechanisms that drive responses to treatments.
Institut National du Cancer, Fondation ARC, China Scholarship Council, Ligue Contre le Cancer du Val de Marne, Fondation de l'Avenir, Ipsen, and Fondation Bristol Myers Squibb Pour la Recherche en Immuno-Oncologie
Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab–bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study
Background Clinical benefits of atezolizumab plus bevacizumab (atezolizumab–bevacizumab) are observed only in a
subset of patients with hepatocellular carcinoma and the development of biomarkers is needed to improve therapeutic
strategies. The atezolizumab–bevacizumab response signature (ABRS), assessed by molecular biology profiling
techniques, has been shown to be associated with progression-free survival after treatment initiation. The primary
objective of our study was to develop an artificial intelligence (AI) model able to estimate ABRS expression directly
from histological slides, and to evaluate if model predictions were associated with progression-free survival.
Methods In this multicentre retrospective study, we developed a model (ABRS-prediction; ABRS-P), which was
derived from the previously published clustering-constrained attention multiple instance learning (or CLAM)
pipeline. We trained the model fit for regression analysis using a multicentre dataset from The Cancer Genome Atlas
(patients treated by surgical resection, n=336). The ABRS-P model was externally validated on two independent series
of samples from patients with hepatocellular carcinoma (a surgical resection series, n=225; and a biopsy series, n=157).
The predictive value of the model was further tested in a series of biopsy samples from a multicentre cohort of
patients with hepatocellular carcinoma treated with atezolizumab–bevacizumab (n=122). All samples in the study
were from adults (aged ≥18 years). The validation sets were sampled between Jan 1, 2008, to Jan 1, 2023. For the
multicentre validation set, the primary objective was to assess the association of high versus low ABRS-P values,
defined relative to cross-validation median split thresholds in the first biopsy series, with progression-free survival
after treatment initiation. Additionally, we performed spatial transcriptomics and matched prediction heatmaps with
in situ expression profiles.
Findings Of the 840 patients sampled, 641 (76%) were male and 199 (24%) were female. Across the development and
validation datasets, hepatocellular carcinoma risk factors included alcohol intake, hepatitis B and C virus infections,
and non-alcoholic steatohepatitis. Using cross-validation in the development series, the mean Pearson’s correlation
between ABRS-P values and ABRS score (mean expression of ABRS genes) was 0·62 (SD 0·09; mean p<0·0001,
SD<0·0001). The ABRS-P generalised well on the external validation series (surgical resection series, r=0·60 [95% CI
0·51–0·68], p<0·0001; biopsy series, r=0·53 [0·40–0·63], p<0·0001). In the 122 patients treated with
atezolizumab–bevacizumab, those with ABRS-P-high tumours (n=74) showed significantly longer median
progression-free survival than those with ABRS-P-low tumours (n=48) after treatment initiation (12 months [95% CI
7–not reached] vs 7 months [4–9]; p=0·014). Spatial transcriptomics showed significantly higher ABRS score, along
with upregulation of various other immune effectors, in tumour areas with high ABRS-P values versus
areas with low ABRS-P values.
Interpretation Our study indicates that AI applied on hepatocellular carcinoma digital slides is able to serve as a
biomarker for progression-free survival in patients treated with atezolizumab–bevacizumab. This approach could be
used in the development of inexpensive and fast biomarkers for targeted therapies. The combination of AI heatmaps
with spatial transcriptomics provides insight on the molecular features associated with predictions. This methodology
could be applied to other cancers or diseases and improve understanding of the biological mechanisms that drive
responses to treatments